Flagship, ProFound set off on obesity drug hunt for Pfizer

pharmaphorum June 13, 2024
Phil Taylor

Pfizer has had some setbacks in its efforts to develop drugs for the lucrative obesity market, but could see its pipeline swell thanks to its $7 billion partnership with venture capital firm Flagship Pioneering.

Flagship has just announced that it will work with biotech start-up ProFound Therapeutics to find first-in-class protein therapeutics with potential in obesity, confirming this is the first programme in the alliance with Pfizer signed last July.

The announcement comes just a few months after Pfizer was forced to abandon two of its obesity candidates. Most recently, it shelved a twice-daily formulation of oral GLP-1 receptor agonist danuglipron after seeing a high dropout rate in a mid-stage clinical trial due to side effects, having previously stopped work...

Today's Sponsors

Today's Sponsor